Coherus Biosciences | CHRS - Trade Debtors


Coherus Biosciences reported $62.44M in Trade Debtors for its fiscal quarter ending in March of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Akebia Therapeutics USD 61.54M 27.17M Mar/2025
ALKERMES USD 334.02M 21.08M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amarin USD 127.31M 8.18M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
Baxter International USD 2.01B 231M Dec/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Coherus Biosciences USD 62.44M 59.9M Mar/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Fujifilm JPY 822.64B 36.85B Dec/2025
Gilead Sciences USD 4.91B 182M Dec/2025
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Merck USD 12.12B 596M Sep/2025
Myriad Genetics USD 118M 19M Sep/2025
Pacira USD 124.07M 8.8M Dec/2025
Perrigo USD 612.8M 31.6M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Teva Pharmaceutical Industries USD 3.71B 101M Dec/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025
Xencor USD 29.3M 7.49M Dec/2025
Zoetis USD 1.59B 49M Dec/2025